S
Signos
Health Tech & Medtech · Burlingame, United States · Founded 2019
Weight Loss Plan | Device | App | CGM | Signos MoreLess
Signos is a health-tech startup that operates in the wellness and weight-loss market. The company offers a wearable device and an accompanying app that help users manage their metabolism and achieve their health goals. The wearable device tracks real-time blood sugar levels and trends, and the app provides personalized recommendations based on the user's unique metabolic response to food.
Signos targets individuals who are looking to lose weight, manage their blood sugar levels, or generally improve their health. The company's business model is subscription-based, where users sign up and subscribe to receive the wearable device and access to the app's features.
The app offers a range of features, including in-app nutritionist support, predictive glucose for meals, fasting and meal timing tips, exercise and activity recommendations, and alerts for glucose spikes. The app's AI technology uses millions of data points to provide these personalized recommendations, helping users make informed decisions about their diet and lifestyle.
Signos generates revenue through its subscription fees. The company also appears to have venture capital backing, suggesting potential for growth and expansion in the future.
In summary, Signos is a health-tech startup offering a wearable device and app that provide personalized recommendations for managing metabolism and improving health. The company operates in the wellness and weight-loss market, serving individuals looking to improve their health and lifestyle.
Keywords: Health-tech, Wearable Device, Metabolism Management, Weight-loss, Blood Sugar Tracking, Personalized Recommendations, Subscription Model, Wellness Market, AI Technology, Venture-backed.
Company overview
Signos company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2019
- Headquarters
- Burlingame, United States
- Employees
- 102
- Open positions
- None listed
- Dealroom signal
- 68.7
Valuation & funding
Signos funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Oct 2023 | $20M | $80M | GV · Cheyenne Ventures · Dexcom Ventures · Samsung Next | ↗ |
| SERIES A✓Equity / VC | Nov 2021 | $13M | $52M | GV | ↗ |
| SEEDEquity / VC | Jan 2021 | $0 | — | Undisclosed | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 98 |
| 2025 | 116 |
| 2024 | 98 |
| 2023 | 93 |
| 2022 | 35 |
| 2021 | 12 |
Growth signals
Signos website traffic
Latest recorded traffic for Signos is 140K monthly website visits, up 70.7% over the last three months. Signos's team declined 12.1% over the past year.
Comparisons
Signos compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Signos's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Signos has talent and traffic
team presence
In the news
Latest news about Signos
Recent press, funding announcements, and product moves mentioning Signos — open to read from the original sources.
Market sentiment
What the market is saying about Signos
An AI-synthesized read of the highest-engagement posts about Signos on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Signos’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.














